Japanese maker of electron microscopes and other scientific/analytical instruments for research and industry.
Japanese maker of electron microscopes and other scientific/analytical instruments for research and industry.
Sells large, high-priced instruments to labs, with service and parts after the sale, so installed machines keep generating income. Government and university budgets and chipmakers' R&D spending drive orders. It also makes electron-beam writers used to draw chip patterns in semiconductor manufacturing.
In one line: Japan's Thermo Fisher for electron microscopes.
Moat: narrow (process know-how, installed base, brand). Deep imaging/spectroscopy know-how and installed base among researchers worldwide.
Headquarters: Tokyo, Japan · Founded: 1949 · Employees: 3,731
Size JEOL (6951.T) is a Japan Health Care company (Medical Specialties) with a market value of $2.12B, the 472nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥6,802 on 18 Nov 2026.
Performance Over six months the shares fell 2.2%, against +3.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue fell 14.8% over the last twelve months (peer median +7.9%); the operating margin is 11.8% (peer median 15.2%).
Valuation It trades at 15.5× forward earnings against a peer median of 24.1× (5th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.9 points below its cost of capital (12.9% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥163B | ¥179B | ¥197B | ¥174B | ¥163B |
| Revenue growth | — | -9% | +13% | +7% | — |
| Gross profit | ¥76.8B | ¥81.1B | ¥90.6B | ¥77.5B | ¥71.0B |
| EBITDA | ¥25.2B | ¥31.5B | ¥40.8B | ¥32.3B | ¥29.1B |
| Net income | ¥15.5B | ¥22.1B | ¥18.7B | ¥21.7B | ¥17.8B |
| Free cash flow | n/a | ¥2.51B | ¥20.1B | ¥12.1B | -¥2.68B |
| Capital expenditure | n/a | ¥15.1B | ¥4.26B | ¥3.48B | ¥6.39B |
| Total debt | ¥9.39B | ¥27.1B | ¥9.28B | ¥15.8B | ¥12.5B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| JEOL 6951.T | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Bruker BRKR | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% |
| Rigaku 268A.T | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6951.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.7% | -0.6% | 4th lowest of 21 |
| 6-month return | -2.2% | +3.1% | 7th lowest of 20 |
| Distance from 52-week high | -26.5% | -18.1% | 8th lowest of 21 |
| Revenue growth (TTM) | -14.8% | +7.9% | lowest of 21 |
| Operating margin | 11.8% | 15.2% | 9th lowest of 21 |
| Forward P/E | 15.5× | 24.1× | 5th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 22.2% | 7.6% | most demanding of 14 |
| Growth delivered (Del g) | +10.2% | +10.4% | 7th lowest of 14 |
| Hurdle (Req g minus delivered) | +12.0 pp | -2.8 pp | most demanding of 14 |
| ROIC minus cost of capital | -1.9 pp | +0.6 pp | 7th lowest of 21 |
| EV / EBITDA | 12.4× | 17.1× | 4th cheapest of 15 |
| Net debt / EBITDA | -1.0× | -0.1× | 6th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| JEOL 6951.T | Japan | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% | +10.2% |
| Establishment Labs ESTA | United States | $2.11B | +1% | +38% | -7% | n/a | n/a | n/a |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $2.13B | +25% | +5% | 7% | 10.2× | -10.2% | +0.4% |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% | +34.5% |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 61.5× | 12.6% | +45.4% |
| Metall Zug METN.SW | Switzerland | $2.19B | +20% | 0% | -10% | 139.8× | n/a | n/a |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.25B | -17% | +8% | 29% | 22.1× | -1.1% | +14.1% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.33B | 0% | +6% | 18% | 28.1× | 11.9% | +19.2% |
| Elekta EKTA-B.ST | Sweden | $2.35B | 0% | -7% | 6% | 15.3× | 10.7% | +4.0% |
| Jafron Biomedical 300529.SZ | China | $2.35B | +3% | +1% | 37% | 24.3× | 6.1% | +0.6% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| Neogen NEOG | United States | $2.42B | +25% | 0% | 0% | 32.6× | n/a | n/a |
| Double Medical Technology 002901.SZ | China | $2.43B | -2% | +13% | 26% | 24.2× | 7.6% | +10.4% |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Medacta MOVE.SW | Switzerland | $2.48B | -28% | +8% | 15% | 24.0× | n/a | n/a |
| EBOS EBO.AX | Australia | $2.50B | +7% | +3% | 3% | 15.7× | 4.7% | +6.8% |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 39.9× | n/a | n/a |